Status: Not yet recruiting
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.
Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 2, 2026Locations: 1
Eligibility criteria
Participants with locally advanced or metastatic RMC histologically confirmed by... [+18]
Participants must not have any other malignancies within the past 2 years except... [+24]